Biotechnology expertise: securing biopharma characterization in the laboratory

In the pharmaceutical industry, bringing a biotherapeutic product to market requires rigorous analytical oversight to demonstrate its identity, structure, purity, and stability. The complexity of therapeutic proteins, antibodies, conjugates, and other biomolecules calls for reliable, robust methods suited to the matrix under study. Incomplete characterization can delay development, weaken a regulatory dossier, or complicate batch-to-batch comparison. That is why strong biotechnology expertise is essential to ensure reliable results and speed up decision-making.

Biopharmaceutical products are highly complex molecules and are very sensitive to production, formulation, and storage conditions. Manufacturers must confirm the primary sequence, verify the intact molecular mass, locate disulfide bonds, assess conformation, and monitor critical modifications. These challenges are at the heart of biopharmaceutical analysis and biopharmaceutical product analysis services, which require robust, interpretable analytical data.

Characterizing a biopharmaceutical product relies on the complementarity of several advanced techniques. FILAB notably uses HPLC-MS/MS for peptide mapping and de novo sequencing, HPLC-HRMS for precise molecular mass determination, as well as SEC-triple detection for mass and solution behavior analysis. Analysis of free sulfhydryl groups and disulfide bonds also helps refine understanding of the biomolecule's structure.

FILAB handles the different stages of the analytical project: needs definition, study plan, method development, validation, and transfer at the client site. This organization enables manufacturers to save time, secure their data, and have a single point of contact for demanding technical issues. The approach is designed to meet the schedule, robustness, and compliance constraints specific to the pharmaceutical sector.

FILAB supports pharmaceutical manufacturers in the development, optimization, validation, and transfer of analytical methods dedicated to biotherapeutic products. The laboratory works on structure confirmation, mass determination, disulfide bond analysis, assessment of secondary and tertiary structures, as well as the analysis of spectroscopic profiles and thermal stability. This tailored approach is part of a drive for analytical performance, controlled timelines, and compliance with the quality requirements of a GMP environment.

Beyond initial characterization, pharmaceutical laboratories need methods capable of supporting development, validation, stability studies, batch-to-batch comparisons, and investigations in the event of deviations. The relevance of the analytical plan relies on the choice of techniques, the quality of execution, and the ability to produce results that can be used for industrial decision-making. The goal is to reduce analytical risk while securing development milestones.

Depending on the objectives of the study, the laboratory can complement this approach with FTIR spectroscopy, circular dichroism, UV/Visible profiles, and DSC for thermal stability. Complementary techniques can also be used for related needs in contaminant control or material-product interaction studies, for example in Pharmaceutical ICP Analysis or HS GC MS Laboratory Analysis.

To get started effectively, it is important to identify the product, the critical attributes to document, the level of development maturity, and the intended use of the data. FILAB can then propose a suitable analytical study plan, select the relevant techniques, and organize the development, validation, or transfer stages. Contacting the laboratory, defining your objectives, sharing your constraints, and having your analytical strategy framed makes it possible to secure your project quickly.